Vedolizumab as first line biologic therapy in elderly patients with contraindications against anti-TNF therapy - A real-world nationwide cohort of patients with inflammatory bowel diseases

M. Attauabi, C. Höglund, J. Fassov, Kenneth Bo Pedersen, H. Bansholm Hansen, S. Wildt, Michael Dam Jensen, A. Neumann, C Lind, H. Albaek Jacobsen, A. M. Popa, Jens Kjeldsen, N Pedersen, A. Molazahi, K. Haderselv, C. Aalykke, Torben Knudsen, W. Cebula, Pia Munkholm, F. BendtsenJ. B. Seidelin, B. Johan

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Original languageEnglish
Article numberP347
JournalJournal of Crohn's and Colitis
Issue numberSuppl. 1
Pages (from-to)S369–S370
Number of pages1
Publication statusPublished - 27. May 2021
Event16th Congress of ECCO Virtual -
Duration: 1. Jul 202110. Jul 2021


Conference16th Congress of ECCO Virtual

Cite this